{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:11:02Z","timestamp":1790655062375,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T00:00:00Z","timestamp":1490659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T00:00:00Z","timestamp":1490659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hypertension is one of the most important, preventable causes of premature morbidity and mortality in the developed world. Aldosterone is a major mineralocorticoid hormone that plays a key role in the regulation of blood pressure and is implicated in the pathogenesis of hypertension and heart failure. Aldosterone synthase (AS, cytochrome P450 11B2, cyp11B2) is the sole enzyme responsible for the production of aldosterone in humans. To determine the effects of increased expression of human aldosterone synthase (hAS) on blood pressure (BP), we established transgenic mice carrying the hAS gene (cyp11B2). We showed that hAS overexpression increased levels of aldosterone in hAS<jats:sup>+\/\u2212<\/jats:sup> mice. On high salt diet (HS), BPs of hAS<jats:sup>+\/\u2212<\/jats:sup> mice were significantly increased compared with WT mice. Fadrozole (an inhibitor of aldosterone synthase) treatment significantly reduced BPs of hAS<jats:sup>+\/\u2212<\/jats:sup> mice on HS. This is the first time overexpression of AS in a transgenic mouse line has shown an ability to induce HP. Specifically inhibiting AS activity in these mice is a promising therapy for reducing hypertension. This hAS transgenic mouse model is therefore an ideal animal model for hypertension therapy studies.<\/jats:p>","DOI":"10.1038\/s41598-017-00461-9","type":"journal-article","created":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T22:44:10Z","timestamp":1490222650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Salt-dependent Blood Pressure in Human Aldosterone Synthase-Transgenic Mice"],"prefix":"10.1038","volume":"7","author":[{"given":"Huiying","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Shatara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Kowala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yansheng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,28]]},"reference":[{"key":"461_CR1","doi-asserted-by":"publisher","unstructured":"Tu, K., Chen, Z., Lipscombe, L. L. & Canadian Hypertension Education Program Outcomes Research, T. Prevalence and incidence of hypertension from 1995 to 2005: a population-based study. CMAJ: Canadian Medical Association journal\u2009=\u2009journal de l\u2019Association medicale canadienne 178, 1429\u20131435, doi:10.1503\/cmaj.071283 (2008).","DOI":"10.1503\/cmaj.071283"},{"key":"461_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","volume":"365","author":"PM Kearney","year":"2005","unstructured":"Kearney, P. M. et al. Global burden of hypertension: analysis of worldwide data. Lancet 365, 217\u2013223, doi:10.1016\/S0140-6736(05)17741-1 (2005).","journal-title":"Lancet"},{"key":"461_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1210\/me.2003-0005","volume":"18","author":"MH Bassett","year":"2004","unstructured":"Bassett, M. H., Suzuki, T., Sasano, H., White, P. C. & Rainey, W. E. The orphan nuclear receptors NURR1 and NGFIB regulate adrenal aldosterone production. Mol Endocrinol 18, 279\u2013290, doi:10.1210\/me.2003-0005 (2004).","journal-title":"Mol Endocrinol"},{"key":"461_CR4","first-page":"1633","volume":"84","author":"Y Takeda","year":"1999","unstructured":"Takeda, Y., Furukawa, K., Inaba, S., Miyamori, I. & Mabuchi, H. Genetic analysis of aldosterone synthase in patients with idiopathic hyperaldosteronism. The Journal of clinical endocrinology and metabolism 84, 1633\u20131637 (1999).","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"461_CR5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1161\/01.HYP.35.3.694","volume":"35","author":"P Mulatero","year":"2000","unstructured":"Mulatero, P. et al. CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism. Hypertension 35, 694\u2013698 (2000).","journal-title":"Hypertension"},{"key":"461_CR6","first-page":"3","volume":"45","author":"JW Conn","year":"1955","unstructured":"Conn, J. W. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. The Journal of laboratory and clinical medicine 45, 3\u201317 (1955).","journal-title":"The Journal of laboratory and clinical medicine"},{"key":"461_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(05)74868-6","volume":"353","author":"PO Lim","year":"1999","unstructured":"Lim, P. O., Rodgers, P., Cardale, K., Watson, A. D. & MacDonald, T. M. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 353, 40, doi:10.1016\/S0140-6736(05)74868-6 (1999).","journal-title":"Lancet"},{"key":"461_CR8","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi, G. P. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. Journal of the American College of Cardiology 48, 2293\u20132300, doi:10.1016\/j.jacc.2006.07.059 (2006).","journal-title":"Journal of the American College of Cardiology"},{"key":"461_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/01.mnh.0000165889.60254.98","volume":"14","author":"NJ Brown","year":"2005","unstructured":"Brown, N. J. Aldosterone and end-organ damage. Current opinion in nephrology and hypertension 14, 235\u2013241 (2005).","journal-title":"Current opinion in nephrology and hypertension"},{"key":"461_CR10","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","volume":"50","author":"C Catena","year":"2007","unstructured":"Catena, C. et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 50, 911\u2013918, doi:10.1161\/HYPERTENSIONAHA.107.095448 (2007).","journal-title":"Hypertension"},{"key":"461_CR11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1056\/NEJM197203022860901","volume":"286","author":"HR Brunner","year":"1972","unstructured":"Brunner, H. R. et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 286, 441\u2013449, doi:10.1056\/NEJM197203022860901 (1972).","journal-title":"N Engl J Med"},{"key":"461_CR12","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez, P. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology 45, 1243\u20131248, doi:10.1016\/j.jacc.2005.01.015 (2005).","journal-title":"Journal of the American College of Cardiology"},{"key":"461_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","volume":"33","author":"R Rocha","year":"1999","unstructured":"Rocha, R., Chander, P. N., Zuckerman, A. & Stier, C. T. Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33, 232\u2013237 (1999).","journal-title":"Hypertension"},{"key":"461_CR14","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha, R. et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141, 3871\u20133878 (2000).","journal-title":"Endocrinology"},{"key":"461_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/ndt\/gfs388","volume":"28","author":"M Azizi","year":"2013","unstructured":"Azizi, M., Amar, L. & Menard, J. Aldosterone synthase inhibition in humans. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 28, 36\u201343, doi:10.1093\/ndt\/gfs388 (2013).","journal-title":"Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"461_CR16","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1161\/01.CIR.0000142858.44680.27","volume":"110","author":"A Garnier","year":"2004","unstructured":"Garnier, A. et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 110, 1819\u20131825, doi:10.1161\/01.CIR.0000142858.44680.27 (2004).","journal-title":"Circulation"},{"key":"461_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1161\/HYPERTENSIONAHA.107.098897","volume":"51","author":"N Makhanova","year":"2008","unstructured":"Makhanova, N., Hagaman, J., Kim, H. S. & Smithies, O. Salt-sensitive blood pressure in mice with increased expression of aldosterone synthase. Hypertension 51, 134\u2013140, doi:10.1161\/HYPERTENSIONAHA.107.098897 (2008).","journal-title":"Hypertension"},{"key":"461_CR18","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1073\/pnas.89.4.1458","volume":"89","author":"T Kawamoto","year":"1992","unstructured":"Kawamoto, T. et al. Role of steroid 11 beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proceedings of the National Academy of Sciences of the United States of America 89, 1458\u20131462 (1992).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"461_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.steroids.2011.10.010","volume":"77","author":"LC Cheng","year":"2012","unstructured":"Cheng, L. C., Pai, T. W. & Li, L. A. Regulation of human CYP11B1 and CYP11B2 promoters by transposable elements and conserved cis elements. Steroids 77, 100\u2013109, doi:10.1016\/j.steroids.2011.10.010 (2012).","journal-title":"Steroids"},{"key":"461_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/(SICI)1097-0029(19970315)36:6<445::AID-JEMT2>3.0.CO;2-H","volume":"36","author":"K Ishimura","year":"1997","unstructured":"Ishimura, K. & Fujita, H. Light and electron microscopic immunohistochemistry of the localization of adrenal steroidogenic enzymes. Microscopy research and technique 36, 445\u2013453, doi:10.1002\/(SICI)1097-0029(19970315)36:6<445::AID-JEMT2>3.0.CO;2-H (1997).","journal-title":"Microscopy research and technique"},{"key":"461_CR21","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/01.HYP.0000203772.78696.67","volume":"47","author":"K Nagata","year":"2006","unstructured":"Nagata, K. et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47, 656\u2013664, doi:10.1161\/01.HYP.0000203772.78696.67 (2006).","journal-title":"Hypertension"},{"key":"461_CR22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.steroids.2008.01.013","volume":"73","author":"W Thomas","year":"2008","unstructured":"Thomas, W., McEneaney, V. & Harvey, B. J. Aldosterone-induced signalling and cation transport in the distal nephron. Steroids 73, 979\u2013984, doi:10.1016\/j.steroids.2008.01.013 (2008).","journal-title":"Steroids"},{"key":"461_CR23","doi-asserted-by":"publisher","unstructured":"Poulsen, S. B. & Christensen, B. M. Long-term aldosterone administration increases renal Na+-Cl- cotransporter abundance in late distal convoluted tubule. American journal of physiology. Renal physiology, ajprenal 00352 02016, doi:10.1152\/ajprenal.00352.2016 (2016).","DOI":"10.1152\/ajprenal.00352.2016"},{"key":"461_CR24","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1056\/NEJMoa003417","volume":"345","author":"RS Vasan","year":"2001","unstructured":"Vasan, R. S. et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. The New England journal of medicine 345, 1291\u20131297, doi:10.1056\/NEJMoa003417 (2001).","journal-title":"The New England journal of medicine"},{"key":"461_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0092-8674(01)00241-0","volume":"104","author":"RP Lifton","year":"2001","unstructured":"Lifton, R. P., Gharavi, A. G. & Geller, D. S. Molecular mechanisms of human hypertension. Cell 104, 545\u2013556 (2001).","journal-title":"Cell"},{"key":"461_CR26","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1146\/annurev.physiol.64.082101.143243","volume":"64","author":"BC Rossier","year":"2002","unstructured":"Rossier, B. C., Pradervand, S., Schild, L. & Hummler, E. Epithelial sodium channel and the control of sodium balance: interaction between genetic and environmental factors. Annual review of physiology 64, 877\u2013897, doi:10.1146\/annurev.physiol.64.082101.143243 (2002).","journal-title":"Annual review of physiology"},{"key":"461_CR27","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s11906-015-0552-2","volume":"17","author":"N Ayuzawa","year":"2015","unstructured":"Ayuzawa, N. & Fujita, T. Activation of mineralocorticoid receptor in salt-sensitive hypertension. Current hypertension reports 17, 552, doi:10.1007\/s11906-015-0552-2 (2015).","journal-title":"Current hypertension reports"},{"key":"461_CR28","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1152\/japplphysiol.00553.2012","volume":"113","author":"A Gabor","year":"2012","unstructured":"Gabor, A. & Leenen, F. H. Central neuromodulatory pathways regulating sympathetic activity in hypertension. Journal of applied physiology 113, 1294\u20131303, doi:10.1152\/japplphysiol.00553.2012 (2012).","journal-title":"Journal of applied physiology"},{"key":"461_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger, M. H., Roniker, B., Krause, S. L. & Weiss, R. J. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. American journal of hypertension 15, 709\u2013716 (2002).","journal-title":"American journal of hypertension"},{"key":"461_CR30","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka, M. K., Zaman, M. A. & Calhoun, D. A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. American journal of hypertension 16, 925\u2013930 (2003).","journal-title":"American journal of hypertension"},{"key":"461_CR31","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman, N. et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49, 839\u2013845, doi:10.1161\/01.HYP.0000259805.18468.8c (2007).","journal-title":"Hypertension"},{"key":"461_CR32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. The New England journal of medicine 341, 709\u2013717, doi:10.1056\/NEJM199909023411001 (1999).","journal-title":"The New England journal of medicine"},{"key":"461_CR33","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The New England journal of medicine 348, 1309\u20131321, doi:10.1056\/NEJMoa030207 (2003).","journal-title":"The New England journal of medicine"},{"key":"461_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad, F. et al. Eplerenone in patients with systolic heart failure and mild symptoms. The New England journal of medicine 364, 11\u201321, doi:10.1056\/NEJMoa1009492 (2011).","journal-title":"The New England journal of medicine"},{"key":"461_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.mce.2009.02.005","volume":"308","author":"C Grossmann","year":"2009","unstructured":"Grossmann, C. & Gekle, M. New aspects of rapid aldosterone signaling. Molecular and cellular endocrinology 308, 53\u201362, doi:10.1016\/j.mce.2009.02.005 (2009).","journal-title":"Molecular and cellular endocrinology"},{"key":"461_CR36","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1161\/01.HYP.0000259797.48382.b2","volume":"49","author":"DW Good","year":"2007","unstructured":"Good, D. W. Nongenomic actions of aldosterone on the renal tubule. Hypertension 49, 728\u2013739, doi:10.1161\/01.HYP.0000259797.48382.b2 (2007).","journal-title":"Hypertension"},{"key":"461_CR37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.steroids.2005.02.004","volume":"70","author":"AS Mihailidou","year":"2005","unstructured":"Mihailidou, A. S. & Funder, J. W. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 70, 347\u2013351, doi:10.1016\/j.steroids.2005.02.004 (2005).","journal-title":"Steroids"},{"key":"461_CR38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1210\/me.2012-1287","volume":"27","author":"N Strushkevich","year":"2013","unstructured":"Strushkevich, N. et al. Structural insights into aldosterone synthase substrate specificity and targeted inhibition. Molecular endocrinology 27, 315\u2013324, doi:10.1210\/me.2012-1287 (2013).","journal-title":"Molecular endocrinology"},{"key":"461_CR39","unstructured":"Lippincott Williams & Wilkins. Illustrated manual of nursing practice. 3rd edn, 864 (Lippincott Williams & Wilkins, 2002)."},{"key":"461_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1161\/01.HYP.20.3.319","volume":"20","author":"M Cirillo","year":"1992","unstructured":"Cirillo, M., Laurenzi, M., Trevisan, M. & Stamler, J. Hematocrit, blood pressure, and hypertension. The Gubbio Population Study. Hypertension 20, 319\u2013326 (1992).","journal-title":"Hypertension"},{"key":"461_CR41","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1124\/jpet.110.167148","volume":"334","author":"DF Rigel","year":"2010","unstructured":"Rigel, D. F. et al. Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone. The Journal of pharmacology and experimental therapeutics 334, 232\u2013243, doi:10.1124\/jpet.110.167148 (2010).","journal-title":"The Journal of pharmacology and experimental therapeutics"}],"updated-by":[{"DOI":"10.1038\/s41598-018-31443-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-00461-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-00461-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-00461-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T03:27:13Z","timestamp":1671766033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-00461-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,28]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["461"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-00461-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,28]]},"assertion":[{"value":"11 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has not been fixed in the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"492"}}